Manufacturer: MindBranch, Inc.
IntroductionOn
October 28th, news broke that AstraZeneca's Casodex 150mg was being withdrawn from its
localized prostate cancer indication in many markets after new data from the IL0025 trail showed an increase in mortality for Casodex versus placebo. Datamonitor's Casodex 150mg provides a timely overview of the impact of these events on AstraZeneca's drug and the prostate cancer market as a whole.ScopeAn overview of the role of Casodex in the treatment of prostate cancerAn analysis of initial and recent results from the IL0023/24/25 placebo
controlled trials in non-metastatic prostate cancer and their significanceAssessment of the impact of Casodex's withdrawal for the treatment of